1-2 of 2
Adam Vilmar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim M. Linton, Adam Vilmar, Mats Jerkeman, Jenny MH Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez-Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E Park, James J Wu, Rubina Siddiqi, John Reitan, Gab Castaigne, Gilles Salles
Journal: Blood
Blood (2022) 140 (Supplement 1): 10296–10299.
https://doi.org/10.1182/blood-2022-162638
Published: 2022
Journal Articles

Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Adam Vilmar, PhD MD, Bente Arboe, Par Josefsson, MD PhD, Christian Poulsen, Jacob Haaber Christensen, Judit Jørgensen, MD PhD, Paw Jensen, Jørn Starklint, Per Troellund Pedersen, Michael Pedersen, Peter de Nully Brown, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1781.
https://doi.org/10.1182/blood.V128.22.1781.1781
Published: 2016